Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
These peptides serve a prescriber population in anti-aging medicine, endocrinology, and metabolic health that had limited alternatives during the restriction period
The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management
Clark CA, et al
Skin & Cosmetic Wounds: GHK-Cu leads for dermal collagen remodeling
On the other hand, this healing evidence as such (Skorjanec et al., 2009
